CA2957224A1 - Method of treating prader-willi syndrome - Google Patents

Method of treating prader-willi syndrome Download PDF

Info

Publication number
CA2957224A1
CA2957224A1 CA2957224A CA2957224A CA2957224A1 CA 2957224 A1 CA2957224 A1 CA 2957224A1 CA 2957224 A CA2957224 A CA 2957224A CA 2957224 A CA2957224 A CA 2957224A CA 2957224 A1 CA2957224 A1 CA 2957224A1
Authority
CA
Canada
Prior art keywords
alkyl
substituted
oxytocin receptor
receptor agonist
selective oxytocin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2957224A
Other languages
English (en)
French (fr)
Inventor
Pascal Danglas
Michael Reidy
Paul Korner
Sudarkodi Alagarsamy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring BV filed Critical Ferring BV
Publication of CA2957224A1 publication Critical patent/CA2957224A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2957224A 2014-09-19 2015-09-14 Method of treating prader-willi syndrome Pending CA2957224A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052957P 2014-09-19 2014-09-19
US62/052,957 2014-09-19
PCT/US2015/049911 WO2016044131A1 (en) 2014-09-19 2015-09-14 Method of treating prader-willi syndrome

Publications (1)

Publication Number Publication Date
CA2957224A1 true CA2957224A1 (en) 2016-03-24

Family

ID=54238564

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2957224A Pending CA2957224A1 (en) 2014-09-19 2015-09-14 Method of treating prader-willi syndrome

Country Status (16)

Country Link
US (3) US10441627B2 (enExample)
EP (2) EP3666258B1 (enExample)
JP (3) JP6599447B2 (enExample)
CN (2) CN112773765A (enExample)
CA (1) CA2957224A1 (enExample)
DK (1) DK3666258T3 (enExample)
ES (2) ES2775425T3 (enExample)
FI (1) FI3666258T3 (enExample)
HR (1) HRP20240166T1 (enExample)
HU (1) HUE065829T2 (enExample)
LT (1) LT3666258T (enExample)
PL (1) PL3666258T3 (enExample)
PT (1) PT3666258T (enExample)
RS (1) RS65144B1 (enExample)
SI (1) SI3666258T1 (enExample)
WO (1) WO2016044131A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2957224A1 (en) * 2014-09-19 2016-03-24 Ferring B.V. Method of treating prader-willi syndrome
US10981955B2 (en) 2017-08-11 2021-04-20 Ferring B.V. Method of manufacturing a pharmaceutical composition
US20190135859A1 (en) 2017-08-11 2019-05-09 Ferring B.V. Method of manufacturing a pharmaceutical composition
US10736894B2 (en) 2018-02-15 2020-08-11 Ovid Therapeutics Inc. Methods of treating developmental syndromes with PDE10A inhibitors
AU2019345313A1 (en) 2018-09-20 2021-03-18 Levo Therapeutics, Inc. Carbetocin drug product and process for preparing same
CN112839632A (zh) * 2018-09-20 2021-05-25 莱沃疗法公司 稳定的鼻内卡贝缩宫素制剂
US20240050494A1 (en) * 2020-12-18 2024-02-15 The General Hospital Corporation Probiotics compositions and method of using the same to enhance growth and social function in children
PL4313106T3 (pl) 2021-03-26 2025-09-01 Ot4B Leczenie dysfagii

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544662B2 (en) 1993-06-17 2009-06-09 Carle Development Foundation Polypeptides useful for appetite suppression
US6894026B1 (en) 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US20070032410A1 (en) 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
WO2008150305A1 (en) 2007-06-07 2008-12-11 Nastech Pharmaceutical Company Inc. Intranasal carbetocin formulations and methods for the treatment of autism
US9023793B2 (en) 2006-09-29 2015-05-05 Retrophin, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
CA2699169A1 (en) 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic uses of intermedin 47 and 53 peptides
CA2704724A1 (en) 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag 5use of a peptide as a therapeutic agent
WO2009033820A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2197463A2 (en) 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Use of rgdspasskp and optionally angiotensin ii as therapeutic agents in the treatment of eg s. pneumoniae infections
HRP20140716T1 (hr) 2008-03-31 2014-08-29 Ferring B.V. Analozi oksitocina
CA2731020A1 (en) 2008-07-18 2010-01-21 Zafgen, Inc. Use of antiangiogenic fumagillins in the treatment of obesity
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
US8853158B2 (en) 2010-05-25 2014-10-07 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods for the treatment of a feeding disorder with onset during neonate development using an agonist of the oxytocin receptor
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
WO2012149472A2 (en) 2011-04-27 2012-11-01 Ignite Institute For Individualized Health Methods, compositions, and kits for treating and preventing neurological conditions
EA026687B1 (ru) 2012-12-21 2017-05-31 Ф. Хоффманн-Ля Рош Аг Пептиды в качестве агонистов окситоцина
KR20150108384A (ko) * 2013-01-17 2015-09-25 에프. 호프만-라 로슈 아게 중추신경계 질병의 치료를 위한 옥시토신 수용체 작용제
EA030091B1 (ru) 2014-06-03 2018-06-29 Ф. Хоффманн-Ля Рош Аг Пептиды, выполняющие роль агонистов окситоцина
CR20160562A (es) 2014-06-06 2017-01-06 Hoffmann La Roche Péptidos como agonistas de la oxitocina
SI3177635T1 (sl) 2014-08-07 2019-01-31 F. Hoffmann-La Roche Ag Postopki za pripravo analogov oksitocina
CA2957224A1 (en) * 2014-09-19 2016-03-24 Ferring B.V. Method of treating prader-willi syndrome

Also Published As

Publication number Publication date
JP6921154B2 (ja) 2021-08-18
FI3666258T3 (fi) 2024-02-09
JP2021098745A (ja) 2021-07-01
CN106714819A (zh) 2017-05-24
HUE065829T2 (hu) 2024-06-28
US20200129584A1 (en) 2020-04-30
US20240082344A1 (en) 2024-03-14
PT3666258T (pt) 2024-02-01
ES2775425T3 (es) 2020-07-27
JP2020019790A (ja) 2020-02-06
SI3666258T1 (sl) 2024-04-30
RS65144B1 (sr) 2024-02-29
CN112773765A (zh) 2021-05-11
EP3666258A1 (en) 2020-06-17
EP3666258B1 (en) 2023-11-15
US10441627B2 (en) 2019-10-15
US20170326200A1 (en) 2017-11-16
JP6599447B2 (ja) 2019-10-30
ES2970059T3 (es) 2024-05-24
WO2016044131A1 (en) 2016-03-24
PL3666258T3 (pl) 2024-04-08
DK3666258T3 (da) 2024-02-05
HRP20240166T1 (hr) 2024-04-26
JP2017532316A (ja) 2017-11-02
EP3193907A1 (en) 2017-07-26
EP3193907B1 (en) 2020-01-01
LT3666258T (lt) 2024-01-10

Similar Documents

Publication Publication Date Title
EP3666258B1 (en) Method of treating prader-willi syndrome
JP5677946B2 (ja) シャルコー・マリー・トゥース病および関連した障害を処置するためのピロカルピンおよびメチマゾールの組み合わせ
JP2021525709A (ja) 自閉症スペクトラム障害の治療のためのカンナビスベースの組成物
BR112020003025A2 (pt) métodos de tratamento de osteoartrite com gel transdérmico de canabidiol
CN106999467A (zh) 治疗认知减退的方法
AU2018383098B2 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
US20170049777A1 (en) Compositions, methods and uses for the treatment of diabetic neuropathies
CA2847624A1 (en) Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof
HK1247847A1 (zh) 四氢-N，N-二甲基-2，2-二苯基-3-呋喃甲胺的对映体(ANAVEX2-73)及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途
US20250082688A1 (en) Compositions and methods for williams syndrome (ws) therapy
US20040142034A1 (en) Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators
CN114761005A (zh) 医学认知治疗
CA3231407A1 (en) Treatment of neurological disorders
IL303006A (en) Use of pyridofidine and analogues for the treatment of Rett syndrome
JP6216913B1 (ja) 医薬組成物
CN118215480A (zh) 神经病症的治疗
JP2017507941A (ja) 機械的な神経損傷を処置するための新規組成物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200911

EEER Examination request

Effective date: 20200911

EEER Examination request

Effective date: 20200911

EEER Examination request

Effective date: 20200911

EEER Examination request

Effective date: 20200911

EEER Examination request

Effective date: 20200911

EEER Examination request

Effective date: 20200911

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240903

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240903

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240903